Driscoll Rimma, an executive vice president at Zoetis Inc., recently reported a transaction involving phantom stock units. This transaction, filed on October 13, 2026, is significant as it reflects the ongoing strategies companies like Zoetis use to manage executive compensation and retention.
Zoetis Inc., known for its work in pharmaceutical preparations, is a key player in the life sciences sector. The company focuses on developing and manufacturing medicines and vaccines for pets and livestock. The recent filing, dated October 9, 2026, documents Rimma's acquisition of 277.77 phantom stock units at a price of $26.17 each, which adds to her existing holdings.
The filing indicates that after this transaction, Rimma owns a total of 6,551.15 shares of Zoetis common stock. The phantom stock units acquired are part of the Zoetis Supplemental Savings Plan, which allows for cash settlement following the executive's separation from service. This plan also includes provisions for transferring units into alternative investment funds, subject to company regulations.
This transaction may impact Zoetis' executive compensation practices and highlight the competitive nature of talent retention in the pharmaceutical industry. As companies strive to attract and keep top talent, the structure of executive compensation remains a crucial area of focus.
The filing does not specify what happens next regarding Rimma's holdings or any further actions related to this transaction.